# Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid

> **NCT02274623** · PHASE1 · COMPLETED · sponsor: **OPKO Health, Inc.** · enrollment: 33 (actual)

## Conditions studied

- Breast Cancer
- Prostate Cancer
- Bone Neoplasms
- Hypocalcemia
- Hyperparathyroidism, Secondary

## Interventions

- **DRUG:** CTAP101 Capsules

## Key facts

- **NCT ID:** NCT02274623
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2017-02-27
- **Final completion:** 2017-03-17
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2019-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02274623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02274623, "Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02274623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*